Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2018 | Research

Cyclizing-berberine A35 induces G2/M arrest and apoptosis by activating YAP phosphorylation (Ser127)

Authors: Wuli Zhao, Hong Liu, Junxia Wang, Mengyan Wang, Rongguang Shao

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2018

Abstract

Background

A35 is a novel synthetic cyclizing-berberine recently patented as an antitumor compound. Based on its dual targeting topoisomerase (top) activity, A35 might overcome the resistance of single-target top inhibitors and has no cardiac toxicity for not targeting top2β. In this study we further explored the biological effects and mechanisms of A35.

Methods

Antitumor activity of A35 was evaluated by SRB and colony formation assay. G2/M phase arrest (especially M) and first damage of M-phase cells were investigated by flow cytometry, cytogenetic analysis, immunofluorescence, co-immunoprecipitation and WB. The key role of phospho-YAP (Ser127) in decreasing YAP nuclear localization, subsequent G2/M arrest and proliferation inhibition were explored by YAP1^−/− cells, mutated Ser127 YAP construct (Ser127A) and TUNEL.

Results

G2/M arrest induced by A35 was independent of p53. M phase cells at low dose were firstly damaged and most damaged-cells accumulated in M phase, and that was a result of preferring targeting top2α by A35, as top2α is essential to push M phase into next phase, and targeting top2α induced cells arrested at M phase. A35 decreased YAP1 nuclear localization by activating YAP phosphorylation (Ser127) which subsequently regulated the transcription of YAP target genes associated with growth and cycle regulation to induce G2/M arrest and growth inhibition.

Conclusions

Our studies suggested the mechanism of G2/M arrest induced by A35 and a novel role of YAP1 (Ser127) in G2/M arrest. As a dual topoisomerase inhibitor characterized by no cardiac toxicity, A35 is a promising topoisomerase anticancer agent and worthy of further development in future.

Kuo CL, Chi CW, Liu TY. The anti-inflammatory potential of berberine in vitro and in vivo. Cancer Lett. 2004;203(2):127–37.CrossRefPubMed

Hwang JM, Wang CJ, Chou FP, Tseng TH, Hsieh YS, Lin WL, Chu CY. Inhibitory effect of berberine on tert-butyl hydroperoxide-induced oxidative damage in rat liver. Arch Toxicol. 2002;76(11):664–70.CrossRefPubMed

Letasiova S, Jantova S, Cipak L, Muckova M. Berberine-antiproliferative activity in vitro and induction of apoptosis/necrosis of the U937 and B16 cells. Cancer Lett. 2006;239(2):254–62.CrossRefPubMed

Lin JP, Yang JS, Lee JH, Hsieh WT, Chung JG. Berberine induces cell cycle arrest and apoptosis in human gastric carcinoma SNU-5 cell line. World J Gastroenterol. 2006;12(1):21–8.CrossRefPubMedPubMedCentral

Chen M, Wang J, Yao SF, Zhao Y, Liu L, Li LW, Xu T, Gan LG, Xiao CL, Shan ZL, et al. Effect of YAP inhibition on human leukemia HL-60 cells. Int J Med Sci. 2017;14(9):902–10.CrossRefPubMedPubMedCentral

Wen Y, Ji Y, Zhang Y, Jiang B, Tang C, Wang Q, Chen X, Jia L, Gu W, Xu X. Knockdown of yes-associated protein induces the apoptosis while inhibits the proliferation of human periodontal ligament stem cells through crosstalk between Erk and Bcl-2 signaling pathways. Int J Med Sci. 2017;14(12):1231–40.CrossRefPubMedPubMedCentral

Takeuchi S, Kasamatsu A, Yamatoji M, Nakashima D, Endo-Sakamoto Y, Koide N, Takahara T, Shimizu T, Iyoda M, Ogawara K, et al. TEAD4-YAP interaction regulates tumoral growth by controlling cell-cycle arrest at the G1 phase. Biochem Biophys Res Commun. 2017;486(2):385–90.CrossRefPubMed

Cabochette P, Vega-Lopez G, Bitard J, Parain K, Chemouny R, Masson C, Borday C, Hedderich M, Henningfeld KA, Locker M, et al. YAP controls retinal stem cell DNA replication timing and genomic stability. elife. 2015;4:e08488.CrossRefPubMedPubMedCentral

Shen Z, Stanger BZ. YAP regulates S-phase entry in endothelial cells. PLoS One. 2015;10(1):e0117522.CrossRefPubMedPubMedCentral

10.

Yang S, Zhang L, Liu M, Chong R, Ding SJ, Chen Y, Dong J. CDK1 phosphorylation of YAP promotes mitotic defects and cell motility and is essential for neoplastic transformation. Cancer Res. 2013;73(22):6722–33.CrossRefPubMed

11.

Li YB, Zhao WL, Wang YX, Zhang CX, Jiang JD, Bi CW, Tang S, Chen RX, Shao RG, Song DQ. Discovery, synthesis and biological evaluation of cycloprotoberberine derivatives as potential antitumor agents. Eur J Med Chem. 2013;68:463–72.CrossRefPubMed

12.

Ha GH, Kim HS, Lee CG, Park HY, Kim EJ, Shin HJ, Lee JC, Lee KW, Lee CW. Mitotic catastrophe is the predominant response to histone acetyltransferase depletion. Cell Death Differ. 2009;16(3):483–97.CrossRefPubMed

13.

Guo L, Liu X, Nishikawa K, Plunkett W. Inhibition of topoisomerase IIalpha and G2 cell cycle arrest by NK314, a novel benzo[c]phenanthridine currently in clinical trials. Mol Cancer Ther. 2007;6(5):1501–8.CrossRefPubMed

14.

Zhao W, He H, Ren K, Zhang H, Chen Y, Shao R. Myofibrillogenesis regulator-1 promotes cell adhesion and migration in human hepatoma cells. Chin Sci Bull. 2013;58(24):3007–14.CrossRef

15.

Zhao W, Zhang C, Bi C, Ye C, Song D, Liu X, Shao R. Sophoridinol derivative 05D induces tumor cells apoptosis by topoisomerase1-mediated DNA breakage. Onco Targets Ther. 2016;9:2805–17.CrossRefPubMedPubMedCentral

16.

Zhao W, Jiang G, Bi C, Li Y, Liu J, Ye C, He H, Li L, Song D, Shao R. The dual topoisomerase inhibitor A35 preferentially and specially targets topoisomerase 2alpha by enhancing pre-strand and post-strand cleavage and inhibiting DNA religation. Oncotarget. 2015;6(35):37871–94.CrossRefPubMedPubMedCentral

17.

Braselmann H, Michna A, Hess J, Unger K. CFAssay: statistical analysis of the colony formation assay. Radiat Oncol. 2015;10:223.CrossRefPubMedPubMedCentral

18.

Katz D, Ito E, Lau KS, Mocanu JD, Bastianutto C, Schimmer AD, Liu FF. Increased efficiency for performing colony formation assays in 96-well plates: novel applications to combination therapies and high-throughput screening. BioTechniques. 2008;44(2):ix–xiv.CrossRefPubMed

19.

Liu J, Mao W, Ding B, Liang CS. ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes. Am J Physiol Heart Circ Physiol. 2008;295(5):H1956–65.CrossRefPubMedPubMedCentral

20.

Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science. 1984;226(4673):466–8.CrossRefPubMed

21.

Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature. 2000;408(6811):433–9.CrossRefPubMed

22.

Mantena SK, Sharma SD, Katiyar SK. Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells. Mol Cancer Ther. 2006;5(2):296–308.CrossRefPubMed

23.

Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 1998;273(10):5858–68.CrossRefPubMed

24.

Sharma A, Singh K, Almasan A. Histone H2AX phosphorylation: a marker for DNA damage. Methods Mol Biol. 2012;920:613–26.CrossRefPubMed

25.

Kuo LJ, Yang LX. Gamma-H2AX - a novel biomarker for DNA double-strand breaks. In Vivo. 2008;22(3):305–9.PubMed

26.

Ben-David U, Cowell IG, Austin CA, Benvenisty N. Controlling the survival of human pluripotent stem cells by small molecule-based targeting of topoisomerase II alpha. Stem Cells. 2014;33(3):1013–9.CrossRef

27.

Chen T, Sun Y, Ji P, Kopetz S, Zhang W. Topoisomerase IIalpha in chromosome instability and personalized cancer therapy. Oncogene. 2014;34(31):4019–31.CrossRefPubMedPubMedCentral

28.

Graves PR, Yu L, Schwarz JK, Gales J, Sausville EA, O'Connor PM, Piwnica-Worms H. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem. 2000;275(8):5600–5.CrossRefPubMed

29.

Sampath D, Cortes J, Estrov Z, Du M, Shi Z, Andreeff M, Gandhi V, Plunkett W. Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood. 2006;107(6):2517–24.CrossRefPubMedPubMedCentral

30.

Hotte SJ, Oza A, Winquist EW, Moore M, Chen EX, Brown S, Pond GR, Dancey JE, Hirte HW. Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret hospital phase II consortium study. Ann Oncol. 2006;17(2):334–40.CrossRefPubMed

31.

Moon S, Kim W, Kim S, Kim Y, Song Y, Bilousov O, Kim J, Lee T, Cha B, Kim M, et al. Phosphorylation by NLK inhibits YAP-14-3-3-interactions and induces its nuclear localization. EMBO Rep. 2017;18(1):61–71.CrossRefPubMed

32.

Keshet R, Adler J, Ricardo Lax I, Shanzer M, Porat Z, Reuven N, Shaul Y. C-Abl antagonizes the YAP oncogenic function. Cell Death Differ. 2015;22(6):935–45.CrossRefPubMed

33.

Cottini F, Hideshima T, Xu C, Sattler M, Dori M, Agnelli L, ten Hacken E, Bertilaccio MT, Antonini E, Neri A, et al. Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. Nat Med. 2014;20(6):599–606.CrossRefPubMedPubMedCentral

34.

Zhao W, He H, Ren K, Li B, Zhang H, Lin Y, Shao RG. MR-1 blocks the megakaryocytic differentiation and transition of CML from chronic phase to blast crisis through MEK dephosphorylation. Blood Cancer J. 2013;3:e107.CrossRefPubMedPubMedCentral

35.

Harvey KF, Zhang X, Thomas DM. The hippo pathway and human cancer. Nat Rev Cancer. 2013;13(4):246–57.CrossRefPubMed

36.

Ravizza R, Gariboldi MB, Passarelli L, Monti E. Role of the p53/p21 system in the response of human colon carcinoma cells to doxorubicin. BMC Cancer. 2004;4:92.CrossRefPubMedPubMedCentral

37.

Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene. 2001;20(15):1803–15.CrossRefPubMed

38.

Williams AB, Schumacher B. p53 in the DNA-Damage-Repair Process. Cold Spring Harb Perspect Med. 2016;6(5). https://doi.org/10.1101/cshperspect.a026070.

39.

Gerić M, Štraser A, Gajski G, Nunić J, Žegura B, Filipič M, Garaj-Vrhovac V. Use of γ-H2AX foci assay on human peripheral blood lymphocytes as sensitive biomarker of exposure. In: 9th symposium of the Croatian radiation protection association: 2013; 2013.

40.

Lakin ND, Jackson SP. Regulation of p53 in response to DNA damage. Oncogene. 1999;18(53):7644–55.CrossRefPubMed

41.

Pan D. The hippo signaling pathway in development and cancer. Dev Cell. 2010;19(4):491–505.CrossRefPubMedPubMedCentral

Title: Cyclizing-berberine A35 induces G2/M arrest and apoptosis by activating YAP phosphorylation (Ser127)
Authors: Wuli Zhao
Hong Liu
Junxia Wang
Mengyan Wang
Rongguang Shao
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2018
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-018-0759-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

HJURP promotes hepatocellular carcinoma proliferation by destabilizing p21 via the MAPK/ERK1/2 and AKT/GSK3β signaling pathways

Artemisinin derivatives inactivate cancer-associated fibroblasts through suppressing TGF-β signaling in breast cancer

SWATH-MS based quantitative proteomics analysis reveals that curcumin alters the metabolic enzyme profile of CML cells by affecting the activity of miR-22/IPO7/HIF-1α axis

Long non-coding RNA MIAT promotes gastric cancer growth and metastasis through regulation of miR-141/DDX5 pathway

IL-6-mediated cross-talk between human preadipocytes and ductal carcinoma in situ in breast cancer progression

Extracellular gamma-synuclein promotes tumor cell motility by activating β1 integrin-focal adhesion kinase signaling pathway and increasing matrix metalloproteinase-24, -2 protein secretion

Keynote webinar | Spotlight on antibody–drug conjugates in cancer